- Option Care Health Dl-,01
- 06 October 2026 14:06:41
Source: Sharecast
The price of $32.05 per share represents a premium of around 37% to Option Care Health’s closing share price on Monday.
Once the deal closes, CD&R will hold a majority interest of around 51%, while McKesson - a healthcare services and pharmaceutical company - will invest approximately $1.4bn for a minority interest of circa 49%. Option Care Health will remain a separate company led by its own management team.
Option Care Health chief executive John C. Rademacher said: "This transaction represents a great outcome for Option Care Health and our stockholders, and I want to thank our board of directors for their rigorous process and diligence.
"For more than 45 years, Option Care Health has helped transform the way infusion therapy is delivered, led by our team members’ unwavering commitment to providing extraordinary care to patients. We will continue to enhance our platform and deepen our partnerships with hospitals and health systems, physicians, payers, and biopharma manufacturers. We are thrilled to have the support of CD&R and McKesson, empowering us to continue investing strategically and accelerate the pace of our advanced technology deployment to improve clinical outcomes and reduce the total cost of care.
"Both firms understand our business and the healthcare industry, and have proven track records of fostering growth for some of the largest and fastest-growing healthcare service businesses globally."
The deal is expected to close in the first half of 2027.
At 1405 BST, Option Care shares were up 33% at $31.07 in pre-market trade.